StockWatch
·

Kimball Electronics, Inc. Q1 FY27 Results

KEQ1 FY27 Results
Filing
MetricValue ($ M)Q1 FY26
Revenue390.806.9%
Total Income390.806.9%
Expenditure378.437.8%
PBT7.8029.1%
Net Profit2.6473.8%
OPM3.17%0.79pp
NPM0.68%2.08pp
EPS0.1173.2%
View full financials

Kimball Electronics Reports Q1 2027 Results with Return to Top-Line Growth; Reaffirms Fiscal 2027 Guidance

05 Nov 2026 · 5 Nov, 3:11 am

Summary

Kimball Electronics reported a solid start to fiscal 2027 with net sales of $390.8 million for the first quarter, marking a 7% increase year-over-year and a 5% increase sequentially. The company achieved 3% organic sales growth across all verticals, with a notable 14% increase in Medical sales. Management expressed encouragement with the results, highlighting healthy margins and improved cash conversion. The company reaffirmed its fiscal 2027 guidance, anticipating net sales at the high end of its previously stated range.

Key Highlights

  1. 1

    Net sales for the first quarter of fiscal 2027 were $390.8 million, an increase of 7% compared to Q1 fiscal 2026.

  2. 2

    Year-over-year organic sales growth was 3%, driven by increases across all verticals.

  3. 3

    Medical sales increased by 14% year-over-year, with 9% organic growth.

  4. 4

    Operating income was $12.4 million, representing 3.2% of net sales, while adjusted operating income margin was 4.3% of net sales.

  5. 5

    Cash Conversion Days remained at a multiyear low of 82.

  6. 6

    The company reiterated its guidance for fiscal 2027, expecting net sales at the high end of the $1,535 - $1,560 million range.

  7. 7

    Open orders stood at $690 million at the end of the quarter.

Management Comments

R

Richard D. Phillips

I’m encouraged by our first quarter results and solid start to fiscal 2027. Sales increased both sequentially and year-over-year, margins were healthy, and cash conversion days were once again at a multiyear low. The top line benefited from organic sales growth and the contribution from Helvoet Polymer Technologies, our recent tuck-in acquisition in the medical CDMO. The organic growth was in line with expectations and driven by a high single-digit increase in Medical. This growth aligns with our strategic focus to balance the portfolio across the verticals. Our excitement for the overall fit and growth opportunities of Helvoet are higher now than ever. With the backdrop of a strong balance sheet, we’re investing in medical growth by integrating Helvoet, ramping operations in Indianapolis, leveraging our capabilities as a full service provider, and unlocking synergies across our global footprint. Fiscal 2027 marks an important milestone in our journey and we are reiterating our guidance for the year with sales expected at the high end of the range, driven by continued strength in the Medical vertical.

Informational and educational content only. Not investment advice.